Velsipity (etrasimod) is a prescription medication used to treat adults (16 years and older) with moderately to severely active ulcerative colitis (UC). Ulcerative colitis is a chronic inflammatory bowel disease causing inflammation and ulcers in the large intestine's lining.
How Velsipity Works
Velsipity works by modulating the activity of sphingosine 1-phosphate receptors (S1PR). This action reduces the number of lymphocytes (a type of white blood cell) in the blood, thereby lessening inflammation in the bowel. The reduction in lymphocyte count is typically around 45% of baseline values at 52 weeks, a result of reversible sequestration.
Key Features of Velsipity
- Treatment for Ulcerative Colitis: Approved for treating moderate to severe ulcerative colitis in adults.
- Oral Medication: Taken once daily by mouth.
- Mechanism of Action: Modulates S1PR, reducing lymphocyte count and inflammation.
- Efficacy: Clinical trials showed improved clinical remission and endoscopic improvement in patients compared to placebo.
- Potential Side Effects: While generally well-tolerated, potential side effects include breathing problems, wheezing, racing heart, fever, general illness, and swollen lymph nodes. Some infections may be life-threatening.
Important Considerations
- Serious Side Effects: Patients should be aware of potential serious side effects and seek immediate medical attention if they occur.
- Individual Response: The effectiveness and side effect profile of Velsipity can vary between individuals.
- Consultation with a Physician: It is crucial to consult with a healthcare professional before starting Velsipity treatment or making any changes to medication regimens. They can assess your individual health status and determine if Velsipity is appropriate for you.
